A noninvasive DNA blood test can identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are most ...
Scientists at @HopkinsMedicine say they found a class of inhibitors that may lead to better, more effective treatments for ...
A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most ...
Recently published Metastatic Castration-resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic castration-resistant ...
Primary Mediastinal Germ Cell Tumors: A Real-World Analysis of Clinical Characteristics, Treatment, and Survival Outcomes From Two Tertiary Cancer Centers in India Abiraterone acetate (AA) is approved ...
The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved substantially over the past decade, with androgen receptor pathway inhibitors, taxanes, poly ...
The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The University of Queensland (UQ), to advance QED-203, a promising new ...
Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
After failure of HT, in addition to secondary hormonal manipulation (antiandrogens, ketoconazole with steroids and estrogens), these are currently the drugs approved by the US FDA for initial therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results